Immunoglobulin genes implicated in glioma risk.

abstract：:Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine designed to induce a broa...

journal_title：Oncoimmunology

authors： Somaiah N,Chawla SP,Block MS,Morris JC,Do K,Kim JW,Druta M,Sankhala KK,Hwu P,Jones RL,Gnjatic S,Kim-Schulze S,Tuballes K,Yishak M,Lu H,Yakovich A,Ter Meulen J,Chen M,Kenney RT,Bohac C,Pollack SM

更新日期：2020-11-19 00:00:00

abstract：:Tumors arise and progress in immunocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis. Host immune cells can mount anti-tumor responses by activation of Toll-like receptors (TLRs). However, emerging data suggests that molecules that negatively regulate TLRs are exploited by t...

journal_title：Oncoimmunology

authors： Standiford TJ,Keshamouni VG

更新日期：2012-05-01 00:00:00

abstract：:Immune responses to tumor antigens have been reported in cancer patients. However, the relevance of such spontaneous immune responses to the clinical course has not been studied extensively. We showed that the overall survival of patients with antibodies against NY-ESO-1 or XAGE1 (GAGED2a) antigen was prolonged in gas...

journal_title：Oncoimmunology

authors： Ohue Y,Wada H,Oka M,Nakayama E

更新日期：2014-12-21 00:00:00

abstract：:Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

journal_title：Oncoimmunology

authors： Adamopoulou E,Naumann U

更新日期：2013-08-01 00:00:00

abstract：:We identified a critical role for receptor for advanced glycation end products (RAGE) in the intratumoral accumulation of myeloid-derived suppressor cells (MDSCs) during pancreatic carcinogenesis. The absence of RAGE markedly delayed neoplasia and limited MDSC accumulation in mice expressing an oncogenic variant of Kr...

journal_title：Oncoimmunology

authors： Vernon PJ,Zeh Iii HJ,Lotze MT

更新日期：2013-05-01 00:00:00

abstract：:Th2-type inflammation has been proposed to facilitate tumor growth. In De Monte et al. (J Exp Med 208:469-478, 2011) we identify in pancreatic cancer a complex cytokine/chemokine cross-talk within the tumor microenvironment mediating Th2 immune-deviation and show that the ratio of Th2/Th1 tumor infiltrating lymphocyte...

journal_title：Oncoimmunology

authors： Protti MP,De Monte L

更新日期：2012-01-01 00:00:00

abstract：:PolyI:C is a nucleotide pattern molecule that induces cross-presentation of foreign Ag in myeloid dendritic cells (DC) and MHC Class I-dependent proliferation of cytotoxic T lymphocytes (CTL). DC (BM or spleen CD8α(+)) have sensors for dsRNA including polyI:C to signal facilitating cross-presentation. Endosomal TLR3 a...

journal_title：Oncoimmunology

authors： Azuma M,Ebihara T,Oshiumi H,Matsumoto M,Seya T

更新日期：2012-08-01 00:00:00

abstract：:A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues. However, different tissues have unique immune components, and very little is known about whether effector T cells induced against tumors in one tissue can wo...

journal_title：Oncoimmunology

authors： O'Konek JJ,Ambrosino E,Bloom AC,Pasquet L,Massilamany C,Xia Z,Terabe M,Berzofsky JA

更新日期：2018-04-09 00:00:00

abstract：BACKGROUND:Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. METHODS:Retrospective analysis of 48 stage IV melanoma ...

journal_title：Oncoimmunology

authors： Boudewijns S,Koornstra RH,Westdorp H,Schreibelt G,van den Eertwegh AJ,Geukes Foppen MH,Haanen JB,de Vries IJ,Figdor CG,Bol KF,Gerritsen WR

更新日期：2016-06-17 00:00:00

abstract：:The tumor microenvironment is characterized by of high levels of extracellular nucleotides that are metabolized through the dynamic and sequential action of cell surface enzymes (ectoenzymes). These ectoenzymes operate according to their spatial arrangement, as part of (1) continuous (molecules on the same cell) or (2...

journal_title：Oncoimmunology

authors： Horenstein AL,Chillemi A,Zaccarello G,Bruzzone S,Quarona V,Zito A,Serra S,Malavasi F

更新日期：2013-09-01 00:00:00

abstract：:This proof-of-concept single-arm open-label phase I clinical trial (NCT02481934) studied the safety and efficacy of multiple infusions of activated and expanded natural killer (NKAE) cells in combination with anti-myeloma drugs in multiple myeloma patients. It included five patients with relapsed or refractory MM who ...

journal_title：Oncoimmunology

authors： Leivas A,Perez-Martinez A,Blanchard MJ,Martín-Clavero E,Fernández L,Lahuerta JJ,Martinez-Lopez J

更新日期：2016-11-22 00:00:00

abstract：:High-dose chemotherapy may kill not only tumor cells but also immunocytes, and frequently induces severe lymphocytopenia. On the other hand, patients who recover from the nadir maintain immunity against infection, suggesting the existence of an unknown memory T-cell population with stress resistance, long-living capac...

journal_title：Oncoimmunology

authors： Murata K,Tsukahara T,Emori M,Shibayama Y,Mizushima E,Matsumiya H,Yamashita K,Kaya M,Hirohashi Y,Kanaseki T,Kubo T,Himi T,Ichimiya S,Yamashita T,Sato N,Torigoe T

更新日期：2016-06-08 00:00:00

abstract：:The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims to establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial of autologous or donor- derived T cells genetically modified to express a CAR targeting the B-cell antigen CD19 harboring 4-1BB and ...

journal_title：Oncoimmunology

authors： Dai H,Zhang W,Li X,Han Q,Guo Y,Zhang Y,Wang Y,Wang C,Shi F,Zhang Y,Chen M,Feng K,Wang Q,Zhu H,Fu X,Li S,Han W

更新日期：2015-05-26 00:00:00

abstract：:In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses. ...

journal_title：Oncoimmunology

authors： Aruga A

更新日期：2013-07-01 00:00:00

abstract：:Cleavage or shedding of the surface antigen, MHC class I chain-related (MIC) protein (A/B) has been known to be one of the mechanisms by which tumor cells escape host immune surveillance. Thus, any strategy to augment the surface expression of MICA/B could facilitate anticancer immune response. Here, we demonstrate th...

journal_title：Oncoimmunology

authors： Fu D,Geschwind JF,Karthikeyan S,Miller E,Kunjithapatham R,Wang Z,Ganapathy-Kanniappan S

更新日期：2015-01-14 00:00:00

abstract：:Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considere...

journal_title：Oncoimmunology

authors： Davola ME,Mossman KL

更新日期：2019-03-28 00:00:00

abstract：:Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyz...

journal_title：Oncoimmunology

authors： Kreutzman A,Yadav B,Brummendorf TH,Gjertsen BT,Hee Lee M,Janssen J,Kasanen T,Koskenvesa P,Lotfi K,Markevärn B,Olsson-Strömberg U,Stentoft J,Stenke L,Söderlund S,Udby L,Richter J,Hjorth-Hansen H,Mustjoki S

更新日期：2019-07-13 00:00:00

abstract：:Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor response to type-II i...

journal_title：Oncoimmunology

authors： Luo N,Formisano L,Gonzalez-Ericsson PI,Sanchez V,Dean PT,Opalenik SR,Sanders ME,Cook RS,Arteaga CL,Johnson DB,Balko JM

更新日期：2018-03-06 00:00:00

abstract：:Anti-PD-1 immunotherapy is the standard of care for treating many patients with non-small cell lung cancer (NSCLC), yet mechanisms of treatment failure are emerging. We present a case of NSCLC, who rapidly progressed during a trial (NCT02318771) combining palliative radiotherapy and pembrolizumab. Planned tumor biopsy...

journal_title：Oncoimmunology

authors： Du S,McCall N,Park K,Guan Q,Fontina P,Ertel A,Zhan T,Dicker AP,Lu B

更新日期：2018-01-29 00:00:00

abstract：:Immunotherapies such as adoptive cell therapy (ACT) are promising treatments for solid cancers. However, relapsing disease remains a problem and the molecular mechanisms underlying resistance are poorly defined. We postulated that the deregulated epigenetic landscape in cancer cells could underpin the acquisition of r...

journal_title：Oncoimmunology

authors： Wylie B,Chee J,Forbes CA,Booth M,Stone SR,Buzzai A,Abad A,Foley B,Cruickshank MN,Waithman J

更新日期：2019-06-03 00:00:00

abstract：:Throughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines as anticancer agents. Such an enthus...

journal_title：Oncoimmunology

authors： Aranda F,Vacchelli E,Eggermont A,Galon J,Sautès-Fridman C,Tartour E,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-12-01 00:00:00

abstract：:Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2...

journal_title：Oncoimmunology

authors： Ma Y,Adjemian S,Galluzzi L,Zitvogel L,Kroemer G

更新日期：2014-01-01 00:00:00

abstract：:We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

journal_title：Oncoimmunology

authors： McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

更新日期：2012-07-01 00:00:00

abstract：:The DNA damage response (DDR), which is frequently activated in cancer cells, has been proposed to operate as an early barrier against oncogenesis. We have recently shown that ATM mediates the spontaneous regression of Eμ-myc-driven murine B-cell leukemia in a natural killer and T cell-dependent manner. The DDR partia...

journal_title：Oncoimmunology

authors： Tang ML,Gasser S

更新日期：2013-06-01 00:00:00

abstract：:Recent breakthroughs in therapeutic modulation of immune cells have led to novel exciting treatments for cancers. Moreover, the cytokine milieu in the tumor microenvironment is important for appropriate immune surveillance. Here, we demonstrate that NF-κB activity in myeloid cells is essential for cytokine-mediated an...

journal_title：Oncoimmunology

authors： Richmond A,Yang J

更新日期：2015-10-20 00:00:00

abstract：:The B7 family and tumor necrosis factor receptor (TNFR) superfamily play a vital role in the T-cell co-stimulatory and co-inhibitory pathways, regulating T-cell activation, tolerance, and exhaustion; therapeutic modulation of these pathways is translated into effective new cancer treatments. Better understanding of th...

journal_title：Oncoimmunology

authors： Chen YP,Zhang J,Wang YQ,Liu N,He QM,Yang XJ,Sun Y,Ma J

更新日期：2017-02-16 00:00:00

abstract：:Donor lymphocyte infusion (DLI) is an established and potentially curative immune therapy for relapsed leukemia after hematopoietic stem cell transplant (HSCT). Herein, we describe the utility of DLI as a tractable model system to glean fresh insights into understanding and predicting effective anti-leukemia immunity....

journal_title：Oncoimmunology

authors： Bachireddy P,Wu CJ

更新日期：2014-03-17 00:00:00

abstract：:Despite the clinical success of anti-PD1 antibody (α-PD1) therapy, the immune mechanisms contributing to the antineoplastic response remain unclear. Here, we describe novel aspects of the immune response involved in α-PD1-induced antitumor effects using an orthotopic Kras (G12D)/p53(R172H)/Pdx1-Cre (KPC) model of panc...

journal_title：Oncoimmunology

authors： D'Alincourt Salazar M,Manuel ER,Tsai W,D'Apuzzo M,Goldstein L,Blazar BR,Diamond DJ

更新日期：2016-03-16 00:00:00

abstract：:Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

journal_title：Oncoimmunology

authors： Edris B,Weiskopf K,Weissman IL,van de Rijn M

更新日期：2012-10-01 00:00:00

abstract：:Egfl7 is an endothelial-specific gene which expression is deregulated in human cancers. We showed that Egfl7 promotes tumor escape from immunity by downregulating the expression of leukocyte adhesion molecules in endothelial cells, thus repressing immune cell extravasation into tumors. ...

journal_title：Oncoimmunology

authors： Pinte S,Soncin F

更新日期：2012-05-01 00:00:00